Lower relapse incidence with HAPLO versus MSD or MUD HCTs for AML patients with KMT2A rearrangement: a study from the Global Committee and the ALWP of the EBMT.

MLA

Ye, Yishan, et al. “Lower Relapse Incidence with HAPLO versus MSD or MUD HCTs for AML Patients with KMT2A Rearrangement: A Study from the Global Committee and the ALWP of the EBMT.” Blood Cancer Journal, vol. 14, no. 1, May 2024, pp. 1–6. EBSCOhost, https://doi.org/10.1038/s41408-024-01072-0.

APA

Ye, Y., Labopin, M., Chen, J., Wu, D., Gedde-Dahl Sr., T., Blaise, D., Socie, G., Forcade, E., Salmenniemi, U., Maury, S., Versluis, J., Bazarbachi, A., Nagler, A., Brissot, E., Li, L., Luo, Y., Shi, J., Ciceri, F., Huang, H., & Mohty, M. (2024). Lower relapse incidence with HAPLO versus MSD or MUD HCTs for AML patients with KMT2A rearrangement: a study from the Global Committee and the ALWP of the EBMT. Blood Cancer Journal, 14(1), 1–6. https://doi.org/10.1038/s41408-024-01072-0

Chicago

Ye, Yishan, Myriam Labopin, Jia Chen, Depei Wu, Tobias Gedde-Dahl Sr., Didier Blaise, Gérard Socie, et al. 2024. “Lower Relapse Incidence with HAPLO versus MSD or MUD HCTs for AML Patients with KMT2A Rearrangement: A Study from the Global Committee and the ALWP of the EBMT.” Blood Cancer Journal 14 (1): 1–6. doi:10.1038/s41408-024-01072-0.